NextBio Announces Translational Medicine Partnership with Sanofi
News May 02, 2013
NextBio has announced a multi-year collaboration with Sanofi aimed at using NextBio Clinical to incorporate patient omics and clinical data into Sanofi's drug research and development, as part of Sanofi's Translational Medicine for Patients (TM4P) program.
NextBio will provide Sanofi with the NextBio Clinical platform for aggregation, standardization and analysis of patient clinical data, next generation sequencing (NGS) and other molecular data across public data sources, Sanofi clinical trials and Sanofi hospital partners.
NextBio's unique data integration platform, user interface and real-time Big Data analytics will allow Sanofi biologists and clinicians to tap into a vast, growing collection of patient data as it becomes available, as a key enabling technology for translational and clinical research.
"Sanofi has long used NextBio as an important component of the company's preclinical research programs," said Saeid Akhtari, President and Chief Executive Officer of NextBio.
Akhtari continued, "The new translational medicine partnership with NextBio, with its Big Data Genomics capabilities, will enable Sanofi to implement patient-centered approaches across all stages of translational and clinical research in several major therapeutic areas, including oncology and diabetes."
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.